Dr. Bardia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2336 Santa Monica Blvd
Ste 304
Santa Monica, CA 90404Phone+1 310-998-4747
Education & Training
All India Institute of Medical SciencesClass of 2003
Certifications & Licensure
CA State Medical License 2024 - 2026
MA State Medical License 2011 - 2025
MD State Medical License 2008 - 2012
MN State Medical License 2007 - 2008- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Start of enrollment: 2017 Dec 12
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endo...Lorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, Carolina Reduzzi, Tania Rossi
Cancer Letters. 2025-01-28 - Immunotherapy for hormone receptor‒positive HER2-negative breast cancer.Fatima Cardoso, Kim M Hirshfield, Kimberly A Kraynyak, Konstantinos Tryfonidis, Aditya Bardia
NPJ Breast Cancer. 2024-12-06 - Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Brea...Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis
Journal of Clinical Oncology. 2024-09-12
Press Mentions
SABCS: Improved Survival for Advanced Breast Cancer, Using Genomics to Identify Patients with High Risk of Recurrence, How race/ethnicity Influence the Risk of Heart Failure in Early-Stage Breast Cancer and MoreDecember 5th, 2024- Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients with HR-Positive, HER2-Negative Breast Cancer Primary Results from TROPION-Breast01October 29th, 2024
- BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22nd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
